首页> 外文期刊>International Journal of Pharmaceutics >Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection
【24h】

Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection

机译:树突式缀合的肽疫苗增强了衣原体衣原体衣原体感染的间隙

获取原文
获取原文并翻译 | 示例
       

摘要

Peptide-based vaccines have emerged in recent years as promising candidates in the prevention of infectious diseases. However, there are many challenges to maintaining in vivo peptide stability and enhancement of peptide immunogenicity to generate protective immunity which enhances clearance of infections. Here, a dendrimer-based carrier system is proposed for peptide-based vaccine delivery, and shows its anti-microbial feasibility in a mouse model of Chlamydia trachomatis. Chlamydiae are the most prevalent sexually transmitted bacteria worldwide, and also the causal agent of trachoma, the leading cause of preventable infectious blindness. In spite of the prevalence of this infectious agent and the many previous vaccine-related studies, there is no vaccine commercially available. The carrier system proposed consists of generation 4, hydroxyl-terminated, polyamidoamine (PAMAM) dendrimers (G4OH), to which a peptide mimic of a chlamydial glycolipid antigen Peptide 4 (Pep4, AFPQFRSATLLL) was conjugated through an ester bond. The ester bond between G4OH and Pep4 is expected to break down mainly in the intracellular environment for antigen presentation. Pep4 conjugated to dendrimer induced Chlamydiaspecific serum antibodies after subcutaneous immunizations. Further, this new vaccine formulation significantly protected immunized animals from vaginal challenge with infectious Chlamydia trachomatis, and it reduced infectious loads and tissue (genital tract) damage. Pep4 conjugated to G4OH or only mixed with peptide provided enhanced protection compared to Pep4 and adjuvant (i.e. alum), suggesting a potential adjuvant effect of the PAMAM dendrimer. Combined, these results demonstrate that hydroxyl terminated PAMAM dendrimer is a promising polymeric nanocarrier platform for the delivery of peptide vaccines and this approach has potential to be expanded to other infectious intracellular bacteria and viruses of public health significance. (C) 2017 Elsevier B.V. All rights reserved.
机译:近年来批次出现了基于肽的疫苗作为预防传染病的承诺候选人。然而,在体内肽稳定性和增强肽免疫原性中存在许多挑战,以产生保护性免疫力,这提高了感染的间隙。这里,提出了一种基于树突式的载体系统,用于肽的疫苗递送,并在衣原体衣原体的小鼠模型中显示出其抗微生物可行性。衣原体是全球最普遍的性传播细菌,也是沙眼的因果因子,是可预防传染性失明的主要原因。尽管这种传染病的患病率和许多先前的疫苗相关的研究,但没有可商购的疫苗。所提出的载体系统由生成4,羟基封端的聚酰胺(PAMAM)树枝状大分子(G4OH)组成,其中衔接糖脂抗原肽4(Pep4,AFPQFRSATLL)的肽模拟通过酯键缀合。预期G4OH和PEP4之间的酯键主要在抗原呈现的细胞内环境中分解。 Pep4与树突式诱导的皮下免疫后的树突诱导的衣原体血清抗体。此外,这种新的疫苗制剂从阴道攻击与传染性衣原体颅瘤显着保护免疫动物,它降低了传染性载荷和组织(生殖器)损伤。与PeP4和佐剂(即明矾)相比,与G4OH共轭或仅与肽混合的Pep4提供增强的保护,表明PAMAM树枝状聚合物的潜在佐剂效应。结合,这些结果表明,羟基封端的PAMAM树枝状聚合物是用于递送肽疫苗的有希望的聚合物纳米载体平台,并且该方法具有扩展到其他传染细胞内细菌和公共健康意义的病毒。 (c)2017年Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号